I-Mab (NASDAQ:NBP) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:NBP) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $9.00 price objective on the stock.

A number of other equities analysts have also commented on the stock. Wall Street Zen lowered shares of I-Mab from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings started coverage on shares of I-Mab in a report on Thursday, February 5th. They issued a “sell (d-)” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, I-Mab presently has an average rating of “Hold” and a consensus price target of $9.00.

I-Mab Price Performance

Shares of NBP stock opened at $2.45 on Wednesday. I-Mab has a 12 month low of $0.62 and a 12 month high of $6.79. The firm has a market cap of $282.46 million, a price-to-earnings ratio of -6.81 and a beta of 1.74. The business has a fifty day moving average price of $3.00.

I-Mab (NASDAQ:NBP) last issued its quarterly earnings data on Tuesday, April 7th. The company reported ($0.30) EPS for the quarter.

Institutional Investors Weigh In On I-Mab

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,715 shares of the company’s stock, valued at approximately $51,000. Hedge funds and other institutional investors own 38.38% of the company’s stock.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.